Walpoth B, Galdikas J, Vorburger T, Altermatt H J, Schaffner T, Althaus U, Billingham M, Morris R
Department of Thoracic and Cardiovascular Surgery, University of Berne, Switzerland.
Eur Surg Res. 1992;24(4):243-8. doi: 10.1159/000129212.
We assessed FK506 (FK) and rapamycin (RPM) in a heterotopic abdominal rat heart transplant model using a major histocompatibility mismatch (DA to LEW). The end point of our study was histologic grading of rejection (Billingham and working formulation) at 1 week. Two doses of FK (2.0 and 8.0 mg/kg p.o., q.d.) and RPM (1.5 and 6.0 mg/kg i.p., q.d.) were compared to allografts without and with ciclosporin (12.5 mg/kg p.o., q.d.) treatment. Results show: (1) weak heartbeat and full rejection on day 5 in all untreated allografts; (2) weak heartbeat and high degree of rejection in groups receiving low doses of FK and RPM; (3) strong heartbeat and mild rejection in both high FK and RPM dose groups comparable to the results of the hearts treated with ciclosporin; (4) 1 animal in each high FK and RPM dose group showed possible signs of toxicity, and (5) the strength of the heartbeat was not a reliable indicator of the efficacy of an immunosuppressive drug. We conclude that even in a major histocompatibility mismatch model at the time of the strongest immune response (1 week), all three tested drugs can reduce the degree of rejection from severe (untreated allografts) to mild if given in an adequate dosage.
我们在一个主要组织相容性不匹配(DA 到 LEW)的异位腹部大鼠心脏移植模型中评估了 FK506(FK)和雷帕霉素(RPM)。我们研究的终点是在 1 周时的排斥反应组织学分级(比林厄姆和工作配方)。将 FK 的两个剂量(2.0 和 8.0 毫克/千克口服,每日一次)和 RPM 的两个剂量(1.5 和 6.0 毫克/千克腹腔注射,每日一次)与未接受和接受环孢素(12.5 毫克/千克口服,每日一次)治疗的同种异体移植进行比较。结果显示:(1)所有未治疗的同种异体移植在第 5 天出现心跳微弱和完全排斥;(2)接受低剂量 FK 和 RPM 的组心跳微弱且排斥程度高;(3)高 FK 和 RPM 剂量组的心跳强劲且排斥轻微,与环孢素治疗的心脏结果相当;(4)高 FK 和 RPM 剂量组各有 1 只动物显示出可能的毒性迹象;(5)心跳强度不是免疫抑制药物疗效的可靠指标。我们得出结论,即使在最强免疫反应时期(1 周)的主要组织相容性不匹配模型中,如果给予足够剂量,所有三种受试药物都可以将排斥程度从严重(未治疗的同种异体移植)降低到轻微。